Phase 1 Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are already on a waiting list for a lung transplant
- People who have been diagnosed with Group 1 pulmonary arterial hypertension (high blood pressure in the lungs of a specific type), confirmed by specific pressure measurements taken during a heart procedure (confirm with trial site)
- People who have been diagnosed with Group 3 pulmonary hypertension, meaning high blood pressure in the lungs caused by a chronic lung disease and/or low oxygen levels, confirmed by specific pressure measurements (confirm with trial site)
- People whose right side of the heart is not pumping well enough, even while receiving high doses of medications to support the heart, and who also show signs such as high pressure in the veins, reduced heart pumping output, elevated waste products in the blood (lactate), or very low urine output (confirm with trial site)
- People aged 18 or older
- People with a body mass index (a measure of body weight relative to height) below 35
- People who have given written consent to participate, either themselves or through a legally authorised representative
Who may not be able to join:
- People who are in the most severe stage of heart shock (known as INTERMACS 1), where blood pressure is critically low and organ function is rapidly declining despite maximum medication support
- People with serious liver problems, shown by a specific blood test result above a certain level in the 24 hours before the procedure
- People with serious kidney problems, shown by a specific blood test result above a certain level in the 24 hours before the procedure
- People who have signs of a recent or acute brain or neurological injury
- People with an active infection, indicated by a combination of a high white blood cell count, a positive blood culture, or a fever
- People who have a blood clot in the right upper chamber of the heart
- People who have received clot-dissolving treatment in the past 30 days, or who have a known blood clotting disorder such as low platelet counts, sickle cell anaemia, or thalassaemia
- People whose right heart failure is caused by a blood clot in the lungs (pulmonary embolism) alone
- People whose right heart failure is caused by blocked heart arteries or by failure of the left side of the heart (WHO Group 2)
- People with certain birth defects of the heart or blood vessels that cause pulmonary hypertension, such as tetralogy of Fallot or pulmonary vein stenosis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ian Makey, MD, Mayo Clinic
Phone: 9049531048
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Survival until transplant
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.